- Home
- NVCR vs RCKT Comparison
NVCR vs RCKT Comparison
Compare NVCR & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- RCKT
- Stock Information
- Founded
- NVCR 2000
- RCKT 1999
- Country
- NVCR Switzerland
- RCKT United States
- Employees
- NVCR N/A
- RCKT N/A
- Industry
- NVCR Medical/Dental Instruments
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- NVCR Health Care
- RCKT Health Care
- Exchange
- NVCR Nasdaq
- RCKT Nasdaq
- Market Cap
- NVCR 1.9B
- RCKT 264.0M
- IPO Year
- NVCR 2015
- RCKT N/A
- Fundamental
- Price
- NVCR $17.77
- RCKT $3.02
- Analyst Decision
- NVCR Buy
- RCKT Buy
- Analyst Count
- NVCR 7
- RCKT 13
- Target Price
- NVCR $32.43
- RCKT $18.50
- AVG Volume (30 Days)
- NVCR 1.5M
- RCKT 4.0M
- Earning Date
- NVCR 07-24-2025
- RCKT 08-04-2025
- Dividend Yield
- NVCR N/A
- RCKT N/A
- EPS Growth
- NVCR N/A
- RCKT N/A
- EPS
- NVCR N/A
- RCKT N/A
- Revenue
- NVCR $621,711,000.00
- RCKT N/A
- Revenue This Year
- NVCR $5.56
- RCKT N/A
- Revenue Next Year
- NVCR $9.19
- RCKT N/A
- P/E Ratio
- NVCR N/A
- RCKT N/A
- Revenue Growth
- NVCR 18.27
- RCKT N/A
- 52 Week Low
- NVCR $14.17
- RCKT $2.19
- 52 Week High
- NVCR $34.13
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- NVCR 52.02
- RCKT 45.25
- Support Level
- NVCR $16.81
- RCKT $2.76
- Resistance Level
- NVCR $18.70
- RCKT $2.96
- Average True Range (ATR)
- NVCR 0.73
- RCKT 0.20
- MACD
- NVCR 0.04
- RCKT 0.16
- Stochastic Oscillator
- NVCR 62.75
- RCKT 88.57
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.